Details

Autor(en) / Beteiligte

• Ma, Caiqi
• Luo, Chuanghua
• Yin, Haofan
• Zhang, Yang
• Xiong, Wenjun
• Zhang, Ting
• Gao, Tianxiao
• Wang, Xi
• Che, Di
• Fang, Zhenzhen
• Li, Lei
• Xie, Jinye
• Huang, Mao
• Zhu, Liuqing
• Jiang, Ping
• Qi, Weiwei
• Zhou, Ti
• Yang, Zhonghan
• Wang, Wei
• Ma, Jianxing
• Gao, Guoquan
• Yang, Xia

Titel

Kallistatin inhibits lymphangiogenesis and lymphatic metastasis of gastric cancer by downregulating VEGF-C expression and secretion

Ist Teil von

• Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018-07, Vol.21 (4), p.617-631

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Tumor-induced lymphangiogenesis and lymphatic metastasis are predominant during the metastasis of many types of cancers. However, the endogenous inhibitors that counterbalance the lymphangiogenesis and lymphatic metastasis of tumors have not been well evaluated. Kallistatin has been recognized as an endogenous angiogenesis inhibitor. Methods and results Our recent study showed for the first time that the lymphatic vessel density (LVD) was reduced in lung and stomach sections from kallistatin-overexpressing transgenic mice. Kallistatin expresses anti-lymphangiogenic activity by inhibiting the proliferation, migration, and tube formation of human lymphatic endothelial cells (hLECs). Therefore, the present study focuses on the relationships of changes in kallistatin expression with the lymphangiogenesis and lymphatic metastasis of gastric cancer and its underlying mechanisms. Our results revealed that the expression of kallistatin in cancer tissues, metastatic lymph nodes, and plasma of gastric cancer patients was significantly downregulated and that the plasma level of kallistatin was negatively associated with the phase of lymph node metastasis. Furthermore, treatment with kallistatin recombinant protein decreased LVD and lymph node metastases in the implanted gastric xenograft tumors of nude mice. Mechanically, kallistatin suppressed the lymphangiogenesis and lymphatic metastasis by downregulating VEGF-C expression and secretion through the LRP6/IKK/IҡB/NF-ҡB signaling pathway in gastric cancer cells. Conclusions These findings demonstrated that kallistatin functions as an endogenous lymphangiogenesis inhibitor and has an important part in the lymphatic metastasis of gastric cancer.